With 10+ years driving stem cell therapeutics successfully through clinical trials, Longeveron is now offering our proven R&D, process development and manufacturing capabilities to select clients for contract development and manufacturing of cell therapies.
Unlike most of the cell therapy CDMOs, we have direct and deep experience manufacturing our own clinical pipeline and working directly with the FDA – know-how that we now bring to your preclinical or clinical cell therapy asset.
Whether your needs are preclinical development, process optimization, or CGMP manufacturing, you can trust our team to bring your therapeutic to the next step in its development, because we’ve been there. And we’ve done that.
“Longeveron was the perfect CDMO partner to produce clinical material for our lead neonatal stem cell-based therapeutic. Their process development and manufacturing expertise exceeded our expectations and will help support the launch of a key Secretome clinical trial. I would highly recommend their contract development and manufacturing services.”
– Vinny Jindal, President and CEO, Secretome Therapeutics
Our facility in Miami, Florida at the Life Science and Technology Park has been designed to develop and produce clinical material for stem cell therapeutics. In addition to our existing space, we are investing additional capital to fully modernize our manufacturing space to dedicate to external cell therapy developers.
At Longeveron, we have in-house, proven experience developing and manufacturing stem cell therapeutics and moving them into the clinic – because we’ve achieved exactly this with our own clinical pipeline. You can trust our team to treat your cell therapy program as if it were our own, because we offer the same quality, scientific skillset, and manufacturing expertise that we bring to our own pipeline.
Longeveron: a transparent, publicly traded cell therapy CDMO that is with you for the long haul.
Click here to replay our KOL event, which was held on August 16, 2023, featuring Sunjay Kaushal, MD, PhD and Ram Kumar Subramanyan, MD, PhD, discussing the potential for Medicinal Signaling Cells (MSCs), such as those making up Longeveron’s Lomecel-B™ injection, to improve the outcome for Hypoplastic Left Heart Syndrome (HLHS) patients.
Click Here to Watch the Replay